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N-acetylgalactosaminyl transferase-3 (GalNAc-T3) is an enzyme involved in the initial glycosylation of mucin-type O-linked
proteins. In the present study, we used immunohistochemistry to examine GalNAc-T3 expression in 215 surgically resected
non-small cell lung cancers. We analysed the biological and clinical importance of GalNAc-T3 expression, especially with
regard to its potential as a prognostic factor. We found that normal bronchial epithelial cells, bronchial gland cells, and alveolar
pneumocytes showed cytoplasmic immunostaining for GalNAc-T3. Low expression of GalNAc-T3, observed in 93 of 215
tumours (43.4%), was found more frequently in tumours from smokers than those from nonsmokers (P=0.001), in squamous
cell carcinomas than nonsquamous cell carcinomas (P50.0001), and in moderately and poorly differentiated tumours than
well differentiated tumours (P=0.0002). Multivariate logistic regression analysis showed that an association of low GalNAc-T3
expression with squamous cell carcinomas was the only one signiﬁcant relationship of GalNAc-T3 expression with various
factors (P50.0001). Moreover, tumours losing GalNAc-T3 expression had a signiﬁcantly higher Ki-67 labelling index than
tumours retaining GalNAc-T3 expression (P=0.0003). Patients with low GalNAc-T3 expression survived a signiﬁcantly shorter
time than patients with high GalNAc-T3 expression in 103 pStage I non-small cell lung cancers (5-year survival rates, 58% and
78%, respectively; P=0.02 by log-rank test) as well as in 61 pStage I nonsquamous cell carcinomas (5-year survival rates, 63%
and 85%, respectively; P=0.03). Low GalNAc-T3 expression was an unfavourable prognostic factor in pStage I non-small cell
lung cancers (hazards ratio, 2.04; P=0.03), and in pStage I nonsquamous cell carcinomas (hazards ratio, 2.70; P=0.03). These
results suggest that GalNAc-T3 is a new marker of non-small cell lung cancers with speciﬁcity for histology and prognosis.
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Lung cancer is one of the leading causes of cancer death world-
wide. Although the management and treatment of non-small cell
lung cancers (NSCLCs) have improved, there is no evidence that
therapeutic advances have resulted in a marked increase of survival
rates. The overall 5-year survival rate remains at less than 15%
(Ginsberg et al, 2001). It is not fully understood why patients with
comparable stages of NSCLC may have different clinical courses
and respond differently to similar treatments. A more sophisticated
understanding of the pathogenesis and biology of these tumours
(Hanahan and Weinberg, 2000; Sekido et al, 2001) could provide
useful information for predicting clinical outcome, individualising
treatment (Harpole et al, 1995; Strauss et al, 1995; Kwiatkowski
et al, 1998; Dosaka-Akita et al, 2001), and identifying molecular
targets of the treatment (Gibbs, 2000).
Oligosaccharides on glycoproteins are altered in tumorigenesis.
These oligosaccharides often play a role in the regulation of the
biological characteristics of tumours in terms of invasion and
metastatic potential (Hakomori, 1989). Each oligosaccharide is
synthesised by a speciﬁc glycosyltransferase (Varki, 1993). The
initial glycosylation of mucin-type O-linked proteins is catalysed
by one of the UDP-N-acetyl-a-D-Galactosamine: polypeptide N-
acetylgalactosaminyl transferases (GalNAc-transferase family of
enzymes) (Hagen et al, 1993; Homa et al, 1993; Wandall et al,
1997;). Three distinct human GalNAc-transferases, GalNAc-T1,
GalNAc-T2, and GalNAc-T3, have been characterised (White et
al, 1995; Bennett et al, 1996; Wandall et al, 1997). Recently another
3 homologue enzymes, GalNAc-T4, GalNAc-T5, and GalNAc-T6,
have been identiﬁed (Bennett et al, 1996, 1998, 1999; Ten Hagen
et al, 1998). Compared with the expression of GalNAc-T1 and
GalNAc-T2, the expression of GalNAc-T3 is highly tissue speciﬁc.
GalNAc-T3 mRNA has been detected in organs that contain secre-
tory epithelial glands (Hagen et al, 1993; Homa et al, 1993; White
et al, 1995; Bennett et al, 1996). It is hypothesised that the differ-
ential expression of GalNAc-T3 may affect the specialised functions
of glycoproteins produced by normal and malignant cells, and that
it is also associated with biological properties of normal and malig-
nant cells (Sutherlin et al, 1997). However, GalNAc-T3 expression
has not been previously examined in human lung cancers, or in
human bronchial epithelial cells and alveolar pneumocytes, from
which lung cancers develop.
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www.bjcancer.comIn the present study, GalNAc-T3 expression was examined by
immunohistochemistry in surgically resected NSCLCs. We
analysed the biological and clinical importance of GalNAc-T3
expression, especially with regard to its potential as a prognostic
factor.
MATERIALS AND METHODS
Tumour specimens and survival data
Primary tumour specimens from 215 NSCLCs were consecu-
tively obtained by surgery from the Hokkaido University
Medical Hospital during 1976 and 1994. The patients with
NSCLCs consisted of 142 men and 73 women. The histologic
classiﬁcation of the tumour specimens was based on World
Health Organization criteria (World Health Organization,
1982). The tumour specimens included 87 squamous cell carci-
nomas, 110 adenocarcinomas, nine large cell carcinomas, and
eight adenosquamous cell carcinomas. Nonsquamous cell carci-
noma included adenocarcinoma, large cell carcinoma and
adenosquamous cell carcinoma. There were 119 Stage I, 18
Stage II, 70 Stage IIIa, one Stage IIIb, and seven Stage IV
tumours. The postsurgical pathologic TNM stage (pTNM) was
determined according to the guidelines of the American Joint
Committee on Cancer (American Joint Committee on Cancer,
1992). Of the 119 patients with pStage I tumours resected with
curative intent, survival was analysed for the 103 patients who
met the following criteria: (1) survived for more than 3 months
after surgery; (2) did not die of causes other than lung cancer
within 5 years after surgery; and (3) were followed for more
than 3 years after surgery (for patients who remained alive).
Sixteen patients did not meet the above criteria (four died with-
in 3 months after surgery, ﬁve died of causes other than lung
cancer within 5 years, and seven had no survival records after
surgery) were excluded from the survival analysis. Of the 103
patients for whom survival was analysed, 54 patients had died
of cancer, including 27 with squamous cell carcinomas, 22 with
adenocarcinomas, three with large cell carcinomas and two with
adenosquamous cell carcinomas. The Karnofsky performance
status was 90% or greater in all these 103 patients. This study
was approved by the Medical Ethical Committees of Hokkaido
University School of Medicine. Because all patients were coded,
they could not be individually identiﬁed.
Construction of the plasmid and preparation of GST fusion
protein
The GalNAcT3 cDNA was cloned into pGEM-Teasy (Promega,
Madison, WI, USA) by RT–PCR using the primers 5'-ATGGCT-
CACCTAAAGCGACTAG-3' and 5'-GAAAGACTCCAGTCAAAAT-
TTCC-3', as described previously (Nomoto et al, 1999). The
EcoRI-Eco47III fragment (amino acid residues 1–178 of the whole
324 amino acids) was cloned into EcoRI-SmaI sites in the pGEX-
6P, and GST fusion protein (GST-GalNAcT3N) was puriﬁed
according to the manufacturer’s protocol(Pharmacia, Uppsala,
Sweden).
Western blot analysis of GST fusion protein
Both GST and GST-GalNAcT3N were separated on a 12% SDS–
PAGE gel and transferred to polyvinylidene diﬂuoride membrane
(Millipore, Bedford, MA, USA) using semidry blotter. Immunoblot
analysis was performed with anti-GST antibody (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and anti-GalNAcT3 anti-
body, which was a rabbit polyclonal antibody against a
synthesised peptide of human GalNAc-T3 (Nomoto et al, 1999)
and was used for immunohistochemistry.
Immunohistochemistry for GalNAc-T3 expression
GalNAc-T3 expression was analysed by immunohistochemistry.
The labelled streptavidin biotin method was used on 4-mm sections
of formalin-ﬁxed, parafﬁn-embedded tissues after deparafﬁnisation.
Brieﬂy, deparafﬁnised tissue sections were microwaved twice in
10 mM citrate buffer (pH 6.0) for 5 min to retrieve the antigeni-
city. The sections were incubated with normal rabbit serum to
block the non-speciﬁc antibody binding sites. The sections were
then incubated with a 1:5000 dilution of rabbit polyclonal anti-
body against a synthesised peptide of human GalNAc-T3
(Nomoto et al, 1999) or with control rabbit non-immunised serum
at 48C overnight. Immunostaining was performed by the biotin-
streptavidin immunoperoxidase method with 3,3'-diaminobenzi-
dine as a chromogen (SAB-PO kit; Nichirei, Tokyo, Japan).
Sections were counterstained with methyl green. GalNAc-T3
expression in normal bronchial epithelial cells, bronchial gland
cells, and alveolar pneumocytes in the same sections served as an
internal positive control. The GalNAc-T3 expression in tumours
was classiﬁed as high or low, according to the proportion of posi-
tively stained tumour cells. Tumours with staining in at least 50%
of cancer cells, were judged as having high GalNAc-T3 expression
(retaining expression of GalNAc-T3). Tumours with staining in less
than 50% of cancer cells, were judged as having low GalNAc-T3
expression (losing expression of GalNAc-T3), as we previously
described (Shibao et al, 2002).
For the Ki-67 staining, the results that were previously reported
(Hommura et al, 2000) were used for the present study.
Statistical analysis
The associations between GalNAc-T3 expression and categorical
variables were analysed by the w
2 test or Fisher’s exact test as
appropriate. The associations between GalNAc-T3 expression and
age or the Ki-67 labelling index (LI) were analysed by Student’s
t-test. To simultaneously examine the effect of more than one
factor on GalNAc-T3 expression, multivariate logistic regression
analysis was used (Cox and Snell, 1989). The survival curves were
estimated using the Kaplan-Meier method, and differences in survi-
val distributions were evaluated by the generalised Wilcoxon test.
Cox’s proportional hazards modelling of factors potentially related
to survival was performed to identify factors with a signiﬁcant
inﬂuence on survival. P values less than 0.05 were considered
statistically signiﬁcant. All tests were two-sided.
RESULTS
To conﬁrm the availability of an anti-GalNAc-T3 polyclonal anti-
body, Western blot analysis of a GST fusion protein (GST-
GalNAcT3N) was performed (Figure 1). Strong signals of the
GST fusion protein were obtained in the immunoblotting with
anti-GalNAc-T3 polyclonal antibody as well as in that with anti-
GST antibody. The speciﬁcity of this anti-GalNAc-T3 polyclonal
antibody was also tested by immunohistochemistry. After incuba-
tion of this antibody with the excess of GST-GalNAcT3N, the
positive immunostaining was abolished (Figure 2).
Typical immunostaining patterns for GalNAc-T3 with this anti-
body in NSCLCs are shown in Figure 3. In tumour cells, GalNAc-
T3 expression was found diffusely in the cytoplasm, or localised in
the Golgi apparatus. Normal bronchial epithelial cells (Figure 3A),
bronchial gland cells (Figure 3B), and alveolar pneumocytes (data
not shown) also expressed GalNAc-T3.
Of the 215 NSCLCs, 122 (56.7%) had high GalNAc-T3 expres-
sion, and 93 (43.3%) had low GalNAc-T3 expression (Table 1).
The status of GalNAc-T3 expression was statistically analysed to
investigate possible correlations with clinical and clinicopathologi-
cal characteristics of NSCLCs. Low expression of GalNAc-T3 was
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British Journal of Cancer (2002) 87(7), 751–755 ã 2002 Cancer Research UKsigniﬁcantly more prevalent in tumours from men than in those
from women (P=0.0001 by the w
2 test) and in tumours from
smokers compared to nonsmokers (P=0.001). Low GalNAc-T3
expression was also more prevalent in squamous cell carcinomas
than nonsquamous cell carcinomas (P50.0001) (Table 1).
GalNAc-T3 expression was not associated with pTNM classiﬁca-
tions and pStage. Multivariate logistic regression analysis showed
a signiﬁcant association of low GalNAc-T3 expression with squa-
mous cell (P50.0001) (Table 2). This relationship between
GalNAc-T3 expression and histology was the only signiﬁcant rela-
tionship between GalNAc-T3 expression and various factors within
the context of the multivariate model. Tumours having low
GalNAc-T3 expression showed a signiﬁcantly higher Ki-67 LI than
tumours having high GalNAc-T3 expression (P=0.0003) (Table 3).
Tumours having low GalNAc-T3 expression also exhibited a high
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Figure 1 Western blotting of GST fusion protein. GST (100 ng) and
GST-GalNAcT3N (200 ng) proteins were loaded on a 12% SDS–PAGE
gel and transferred to membrane. Immunoblot analysis was performed with
an anti-GalNAcT3 antibody (left) and anti-GST antibody (right). IB,
immunoblotting.
Figure 2 Immunoreactivity of an anti-GalNAc-T3 polyclonal antibody.
Immunostaining was performed with this antibody in a NSCLC specimen
after incubation of this antibody with excess of GST (A) or GST-Gal-
NAcT3N (B). Scale bar=20 mm.
Figure 3 Immunohistochemical staining patterns for GalNAc-T3. Nor-
mal bronchial epithelial cells (A) and bronchial gland cells (B) showed Gal-
NAc-T3 expression. GalNAc-T3 expression was found diffusely in the
cytoplasm of tumour cells or localised in the Golgi apparatus in an adeno-
carcinoma (C), but not seen in a squamous cell carcinoma (D). Scale
bar=20 mm.
Table 1 Relationship between GalNAc-T3 expression and clinical and
clinicopathological characteristics in 215 surgically resected NSCLCs
GalNAc-T3 expression
Characteristics Low High P
Age (mean+s.d.) 63.9+9.0 62.4+9.4 0.2
Sex
Male 75 67 0.0001
Female 18 55
Smoking
Nonsmoker 15 45 0.001
Smoker 72 69
Smoking (pack years)
04, 520 18 49 0.001
420 69 64
Histology
a
Squamous 58 29 50.0001
Adeno 28 83
Others 7 10
Differentiation
Well 9 42 0.0002
Moderate 40 37
Poor 27 20
pT classiﬁcation
1 22 41 0.2
2–4 70 81
pN classiﬁcation
0 60 71 0.4
1–3 32 51
pM classiﬁcation
0 90 117 0.7
12 5
pStage
1 53 66 0.6
28 1 0
3a 29 41
3b 1 0
42 5
aSquamous, squamous cell carcinoma; adeno, adenocarcinoma; others, large cell
carcinoma and adenosquamous cell carcinoma.
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expression (P=0.0003).
We analysed the relationship between GalNAc-T3 expression
and postsurgical survival in pStage I NSCLCs (Figure 4). When
the 103 pStage I NSCLCs were evaluated together, patients with
tumours having low GalNAc-T3 expression survived a signiﬁcantly
shorter time than patients with tumours having high expression (5-
year survival rates, 58% and 78%, respectively, by the Kaplan-
Meier method; P=0.02 by the generalised Wilcoxon test) (Figure
4A). When only patients with 43 squamous cell carcinomas were
analysed, GalNAc-T3 expression did not show a signiﬁcant effect
on survival (5-year survival rates, 54% for low GalNAc-T3 and
57% for high GalNAc-T3; P=0.8). Among 61 nonsquamous cell
carcinoma patients, patients with tumours having low GalNAc-T3
expression survived a signiﬁcantly shorter time than patients with
tumours having high expression (5-year survival rates, 63% and
85%, respectively; P=0.03) (Figure 4B).
The importance of GalNAc-T3 as a prognostic factor was
analysed by the Cox’s proportional hazards model analysis in
patients with pStage I NSCLCs (Table 4). Univariate analysis of
potential prognostic factors revealed that low expression of
GalNAc-T3 was the only statistically signiﬁcant unfavourable prog-
nostic factor in overall NSCLCs (hazards ratio, 2.04; P=0.03) and
in nonsquamous cell carcinomas (hazards ratio, 2.70; P=0.03).
GalNAC-T3 expression was not a prognostic factor in squamous
cell carcinomas (hazards ratio, 0.91; P=0.8).
DISCUSSION
In the present study, GalNAc-T3 expression was frequently
decreased in NSCLCs, although it was expressed in normal bron-
chial epithelial cells, bronchial gland cells and alveolar
pneumocytes. Furthermore, low GalNAc-T3 expression of NSCLCs
was associated with a shorter survival period, and was an unfavour-
able prognostic factor.
The ﬁnding that GalNAc-T3 expression was retained more
frequently in nonsquamous cell carcinomas (most of which were
adenocarcinomas) than in squamous cell carcinomas may reﬂect
tissue speciﬁc expression of GalNAc-T3 in organs that contain
secretory epithelial glands (Hagen et al, 1993; Homa et al,
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Table 2 Multivariate logistic regression analysis for the correlation
between GalNAc-T3 expression and various characteristics
Characteristics
b Odds ratio 95% CI
b P
Gender (male/female) 1.56 0.45–5.36 0.5
Smoking (smoker/nonsmoker) 0.82 0.23–2.87 0.8
Histology (squamous/nonsquamous
c) 5.05 2.25–11.36 50.0001
Differentiation (moderate and poor/well) 3.14 1.25–7.90 0.1
aSelected from Table 1.
bConﬁdence interval.
cIncluding adenocarcinoma, large cell
carcinoma, and adenosquamous cell carcinoma.
Table 3 Relationship between GalNAc-T3 expression and Ki-67 cell
growth fractions in NSCLCs
GalNAc-T3 expression
Characteristics Low High P
Ki-67
LI
a (mean+s.d.) 44.2+25.5 30.6+27.0 0.0003
Low LI
b 29 67 0.0003
High LI
c 62 51
aLI, labelling index.
bLow LI, 530% of tumour cells stained.
cHigh LI, 530% of
tumour cells stained.
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Figure 4 Kaplan–Meier survival curves of patients with pStage I
NSCLCs stratiﬁed by GalNAc-T3 expression. Survival curves of patients
with overall NSCLCs (A) and with nonsquamous cell carcinomas (B) are
stratiﬁed by low and high GalNAc-T3 expression. Nonsquamous cell carci-
noma included adenocarcinoma, large cell carcinoma and adenosquamous
cell carcinoma.
Table 4 Cox’s proportional hazards model analysis of prognostic factors
in patients with pStage I NSCLCs
A Overall NSCLCs
Characteristics Hazards ratio 95% CI
a P
Sex (male/female) 0.63 0.35–1.16 0.1
Age (565/565) 0.75 0.43–1.31 0.3
Chemotherapy 1.24 0.72–2.15 0.4
Histology (nonsquamous
b/squamous) 1.34 0.77–2.35 0.3
Differentiation (moderate, poor/well) 0.89 0.44–1.80 0.8
pT classiﬁcation (pT2/pT1) 1.15 0.66–2.00 0.6
GalNAc-T3 expression (high/low) 2.04 1.09–3.85 0.03
B Nonsquamous cell carcinomas
b
Characteristics Hazards ratio 95% CI
a P
Sex (male/female) 0.72 0.33–1.55 0.4
Age (565/565) 0.70 0.32–1.51 0.8
Chemotherapy 1.42 0.63–3.20 0.4
Differentiation (moderate, poor/well) 0.96 0.38–2.43 0.9
pT classiﬁcation (pT2/pT1) 1.33 0.61–2.87 0.5
GalNAc-T3 expression (high/low) 2.70 1.08–6.76 0.03
aConﬁdence interval.
bIncluding adenocarcinoma, large cell carcinoma, and adenos-
quamous cell carcinoma.
GalNAc-T3 expression in NSCLCs
H Dosaka-Akita et al
754
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nonsquamous cell carcinomas, decreased expression of GalNAc-
T3 was associated with unfavourable prognosis. Consistent with
these results, we have recently found that GalNAc-T3 is
expressed in normal epithelial cells and gland cells of the colon,
and that decreased expression of GalNAc-T3 is an unfavourable
prognostic factor in adenocarcinomas of the colon (Shibao et al,
2002).
The mechanism underlying the relationship between decreased
GalNAc-T3 expression and poor prognosis remains to be deter-
mined. Bronchial and alveolar epithelia, from which NSCLCs
develop, normally express GalNAc-T3. Decreased GalNAc-T3
expression may induce decreased level of glycosylation in certain
types of glycoprotein, resulting in altered functions of the glyco-
proteins. Therefore, the biological importance of GalNAc-T3
expression depends on the function of target substrate glycopro-
teins. The importance of GalNAc-T3 expression for the
development and progression of cancer as well as for maintaining
physiologic properties of normal cells also remains to be deter-
mined, although certain cancer-associated decreases or increases
in glycosylation has been shown to directly contribute to cellular
transformation (Vavasseur et al, 1994; Demetriou et al, 1995).
Collectively, decreased expression of GalNAc-T3 may directly
contribute to altered biological properties of NSCLCs. In fact, in
this study, low expression of GalNAc-T3 in NSCLCs was associated
with a higher LI of Ki-67 cell growth fractions, and resulted in
shorter survival times.
In conclusion, these results indicate that GalNAc-T3 is a new
marker of NSCLCs with speciﬁcity for histology and survival.
GalNAc-T3 expression may be useful to stratify patients with
pStage I tumours into groups at high and low risks of recurrence
in NSCLCs, especially in nonsquamous cell carcinomas.
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